UBS Cuts Price Target on PharMerica (PMC); Risks Continue Building and Mixed Commentary Isn't Settling
Tweet Send to a Friend
UBS maintains a 'Neutral' on PharMerica (NYSE: PMC) price target of $11.50 (from $13.00).
Analyst, Steven Valiquette, said, "After ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Steven Valiquette, said, "After ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
